

Q3 2026 Earnings Presentation

November 4, 2026

Safe Harbor Statement


This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's future financial performance, including its outlook and expected revenue for the year ended December 31, 2026; Cytek's growth and business strategies, product plans and expectations, market trends and opportunities, and any expectations or assumptions thereto; Cytek's ability to effectively navigate uncertain times and strengthen its competitive position as a market leader; Cytek's ability to successfully implement its operational plans and business strategies, including, but not limited to, its ability to expand its global installed base and grow its recurring revenue streams; Cytek's potential for sustainable growth and profitability; and any statements regarding current or future macroeconomic trends or events and the impact of those trends and events on Cytek and its financial performance. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or the negatives of these terms or variation of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, without limitation, global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission (the "SEC") on August 5, 2026, and Cytek's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, to be filed with the SEC on or about the date hereof, and other filings Cytek makes with the SEC from time to time. Unless otherwise indicated, these forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

This presentation and the related conference call and webcast include certain financial information in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") and also on a non-GAAP basis for the three- and nine-month periods ended September 30, 2026 and 2025. Management believes that non-GAAP financial measures, including "Adjusted gross profit," "Adjusted gross margin," "Adjusted EBITDA," and "Adjusted EBITDA excluding investment income," taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company's core operating results. Management uses non-GAAP measures to compare the company's performance relative to forecasts and strategic plans and to benchmark the company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the tables accompanying this presentation.

Cytek, the Cytek logo, Cytek Aurora, Cytek Borealis, FSP, SpectroFlo and Northern Lights are trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders.

Q3 2026 Revenue Results[1]



1. As of quarter ended 9/30/2026. $ Millions
2. Recurring revenue is comprised of service and reagent revenue

Q3 2026 Commentary


Q3 revenue of $53.2M, up 2% Y/Y and 11% sequentially, driven by strong demand for high-end instruments and service growth

Q3 2026 Revenue grew 2% Y/Y driven by:

- High-end FSP instrument revenue up 11%, led by Aurora Evo
- Aurora Evo placements nearly doubled Y/Y, reflecting robust demand for our next-generation platform
- Service revenue up 13%, continuing to grow our recurring revenue base

CYTEK
TRANSCEND THE CONVENTIONAL

Revenue by Geographic Region[1]



Q3 2026 Commentary

US: Revenue up 12% Y/Y on strong high-end instrument demand and continued service growth

EMEA: Revenue up 1% Y/Y, marking a return to growth in the region

APAC: Including China, revenue up 5% sequentially versus Q2 2026, led by higher instrument sales

1. EMEA = Europe, Middle East, & Africa; APAC = Asia-Pacific. $ Millions

Q3 Business Highlights[1]

High-end instruments drove growth in Q3, with high-end FSP instrument revenue up 11% Y/Y, led by Aurora Evo

Delivered excellent gross margin of 59%, increasing 590 bps Y/Y, and the best third quarter result since 2023

Grew Cytek Cloud to nearly 30K users in Q3 2026, up more than 20% since the start of the year

Recurring revenue was $19.1M, up 11% Y/Y, representing 36% of Cytek revenue over the trailing twelve months, up from 33% from a year ago

Aurora Evo placements nearly doubled Y/Y following the Q2'26 launch of automation configurations, driven by demand for larger panels and reproducible data at higher throughput


Doubled the size of the Borealis early-access program -- customer feedback emphasizes the unique value of 60+ color panels for biopharma discovery and clinical research.

1. Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Completing the end-to-end flow cytometry workflow

INTRODUCING THE NEW

Cytek Cloud Analysis




- Launched in Q3: panel design to data analysis in one system
- SpectroFlo data imports directly; pick up analysis where you left off
- Reduces data transfers and recreated worksheets, plots, and gates
- Cloud Premium adds online data storage for U.S. customers

From data to insight, in one platform


Revenue Mix

By Region



12% Y/Y US Growth

Product & Service



13% Y/Y Service Growth

In $ Millions

Q3 2026 Financial Overview

$ in millions	Q3 2025	Q3 2026	Y/Y
Total Revenue	$52.3	$53.2	2%
Gross Profit	$27.6	$31.2	13%
Gross Margin	53%	59%	+590bps
Operating Expenses:			
Research and Development	$9.0	$9.4	4%
Sales and Marketing	$11.7	$11.9	2%
General and Administrative[1]	$16.1	$18.4	14%
Total Operating Expenses	$36.7	$39.6	8%
Loss from Operations	$(9.2)	$(8.4)	-8%
Net Loss	**$(5.5)**	**$(6.1)**	
Non-GAAP Adjusted EBITDA[2]	**$2.5**	**$0.7**	

1. Year-over-year increase in General and Administrative expenses was primarily due to a $3 million increase in legal expenses associated with the company's active patent litigation
2. See Appendix for reconciliation of GAAP to non-GAAP figures

CYTEK
TRANSCEND THE CONVENTIONAL

Reiterating 2026 revenue guidance at the midpoint while narrowing the range

FY 2026 Revenue Guidance[1]

$208 - $211

million

+3% to +5% Y/Y growth

1. Assumes no change from current currency exchange rates

2026 Strategic Priorities

Global Diversification

Accelerate **market penetration of instruments** across multiple geographies

Technology Platform Leader

Advance technological leadership with continuous **innovation**

Growing Recurring Revenue

Drive **reagent and service businesses** benefitting from established and **expanding global installed base**

Attractive Financial Profile

Well-positioned to deliver long-term profitable, sustainable growth through differentiated technology portfolio, durable growth drivers, strong balance sheet, and global reach

CYTEK
TRANSCEND THE CONVENTIONAL

CYTEK®
TRANSCEND THE CONVENTIONAL

Appendix

Reconciliation of GAAP to Non-GAAP Measures (Unaudited)

(In thousands)	Three Months Ended		Nine Months Ended	
	September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
GAAP gross profit	$ 31,206	$ 27,551	$ 80,800	$ 71,575
Stock based compensation	$ 711	$ 906	$ 2,176	$ 3,102
Amortization of acquisition-related intangible assets	$ 490	$ 481	$ 1,474	$ 1,455
Non-GAAP adjusted gross profit	**$ 32,407**	**$ 28,938**	**$ 84,450**	**$ 76,132**
GAAP gross margin	59%	53%	56%	51%
Non-GAAP adjusted gross margin	61%	55%	58%	55%
GAAP net income	**$ (6,097)**	**$ (5,478)**	**$ (37,121)**	**$ (22,463)**
Depreciation and amortization	$ 3,109	$ 3,063	$ 8,906	$ 8,932
Provision for (benefit from) income taxes	$ (811)	$ (2,291)	$ 1,197	$ (3,347)
Interest income	$ (1,024)	$ (573)	$ (2,630)	$ (1,636)
Interest expense	$ 260	$ 494	$ 803	$ 1,199
Foreign currency exchange loss (gain)	$ 421	$ 886	$ 2,301	$ (1,985)
Stock based compensation	$ 4,853	$ 5,638	$ 15,054	$ 19,058
Non-recurring deferred ATM facility offering cost write-off	$ —	$ 711	$ —	$ 711
Write-off Investment	$ —	$ —	$ 1,587	$ —
Non-GAAP adjusted EBITDA	**$ 711**	**$ 2,450**	**$ (9,903)**	**$ 469**
Investment income	$ (1,231)	$ (1,960)	$ (4,244)	$ (6,269)
Non-GAAP adjusted EBITDA excluding investment income	**$ (520)**	**$ 490**	**$ (14,147)**	**$ (5,800)**

CYTEK®
TRANSCEND THE CONVENTIONAL

Thank You